Medicare核准390.75美元的血液测试补偿,该测试预测糖尿病肾脏疾病可提前4年进行。 Medicare approves $390.75 reimbursement for a blood test that predicts diabetic kidney disease up to four years early.

美国CMS为Proteomics International的PromarkerD血液测试设定了390.75美元的补偿率,该测试是一种指尖诊断,用蛋白质和临床生物标志预测糖尿病肾脏疾病在症状出现前4年。 The U.S. CMS has set a $390.75 reimbursement rate for Proteomics International’s PromarkerD blood test, a finger-prick diagnostic that predicts diabetic kidney disease up to four years before symptoms, using protein and clinical biomarkers. 通过将PLA代码赋予测试的决定, 开启了医疗保险的覆盖范围, 并为私人保险公司设定了基准. The decision, assigning the test a PLA code, unlocks Medicare coverage and sets a benchmark for private insurers. 每年有超过3 200万美国人患有糖尿病和糖尿病肾脏疾病,耗资1 300亿美元。 测试在预测肾脏下降方面准确率达到86%,这为通过经证实的疗法进行早期干预提供了潜力。 With over 32 million Americans with diabetes and diabetic kidney disease costing $130 billion annually, the test’s 86% accuracy in predicting kidney decline offers potential for early intervention with proven therapies. 这项裁决加速了Proteomics计划的2026年全国推广,并得到了CLIA认证实验室的支持,并努力确保了更广泛的保险覆盖。 The ruling accelerates Proteomics’ planned 2026 national rollout, supported by a CLIA-certified lab and efforts to secure broader insurer coverage. 该公告将公司股价提升高达29%, 反映市场信心强。 The announcement boosted the company’s share price by up to 29%, reflecting strong market confidence.